Cargando…
World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer
Autor principal: | Liu, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772009/ https://www.ncbi.nlm.nih.gov/pubmed/33392608 http://dx.doi.org/10.1055/s-0040-1721451 |
Ejemplares similares
-
Recent Advances in Genome Editing Using CRISPR/Cas9
por: Ding, Yuduan, et al.
Publicado: (2016) -
Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022) -
Genome editing of immune cells using CRISPR/Cas9
por: Kim, Segi, et al.
Publicado: (2021) -
Recent Advances in CRISPR/Cas9-Mediated Genome Editing in Dictyostelium
por: Muramoto, Tetsuya, et al.
Publicado: (2019) -
Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy
por: Santos, Renato, et al.
Publicado: (2019)